Oncopeptides Ab Publ

Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug, Pepaxti, is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere. Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE. The company was founded in has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO. For more information, visit: